Botanix Pharmaceuticals (ASX:BOT) said it is unlikely to be affected by a proposed US executive order that would tie US drug prices to the lowest price paid by any other country globally, according to a Monday filing with the Australian bourse.

The company confirmed that its topical gel to treat excessive underarm sweating, Sofdra, is marketed exclusively in the US and is not sold in any other countries, the filing said.

Botanix added that it will review the proposed order when available.